Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H22O10 |
Molecular Weight | 482.4362 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC=C1O)[C@H]2OC3=CC(=CC=C3O[C@@H]2CO)[C@H]4OC5=C(C(=O)[C@@H]4O)C(O)=CC(O)=C5
InChI
InChIKey=SEBFKMXJBCUCAI-HKTJVKLFSA-N
InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
Molecular Formula | C25H22O10 |
Molecular Weight | 482.4362 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17305535 | http://www.webmd.com/heart-disease/milk-thistle-benefits-and-side-effects#1
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/17305535 | http://www.webmd.com/heart-disease/milk-thistle-benefits-and-side-effects#1
Silymarin, a plant-derived flavonoid from the plant Silybum marianum, is considered the most potential drug to treat almost all kind of liver diseases, particularly alcoholic liver disease, acute and chronic viral hepatitis and toxins-mediated liver dysfunctions. The main component of the silymarin complex is silybin, synonymous with silibinin, sometimes incorrectly called silybinin, which is a mixture of two diastereomers A and B in approximately 1:1 proportion. The drug possess hepatoprotective and antioxidant activity. The hepatoprotective effect is due to stimulation of synthesis of structural and functional proteins and phospholipids, as well as acceleration of the regeneration of hepatocytes. Antioxidant effect is determined by interaction of bioflavones with free radicals in the liver and its detoxication. In such manner the process of peroxidation of the lipids is interrupted and further liver destruction is prevented. Side effect is a mild laxative effect has occasionally been observed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006979 |
|||
Target ID: CHEMBL3021 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14568570 |
|||
Target ID: CHEMBL4302 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date2000 |
|||
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date2000 |
|||
Primary | Milk Thistle Approved UseIt is indicated for the treatment of jaundice, chronic inflammatory liver conditions, i.e. hepatitis, alcoholic liver damage and hepatic cirrhosis. Launch Date2000 |
PubMed
Title | Date | PubMed |
---|---|---|
MDR- and CYP3A4-mediated drug-herbal interactions. | 2006 Mar 27 |
|
Identification of hepatoprotective flavonolignans from silymarin. | 2010 Mar 30 |
|
Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. | 2012 Feb |
|
Silibinin potentially protects arsenic-induced oxidative hepatic dysfunction in rats. | 2012 May |
|
Blockade of lipid accumulation by silibinin in adipocytes and zebrafish. | 2015 Feb 5 |
Sample Use Guides
70 mg or 140 mg capsule should be taken 3 times daily. The medication should be continued until the relief of the symptoms according to the advice of a physician.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17305535
Silybin at pharmacologically achievable in vivo concentrations (0.02–20 uM) increased insulin-like growth factorbinding protein 3 (IGFBP-3) accumulation in androgenindependent prostate cancer PC-3 cells in conditioned medium and caused a dose-dependent increase of IGFBP-3 mRNA abundance with a 9-fold increase over baseline at 20 uM concentration.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:01:35 GMT 2023
by
admin
on
Fri Dec 15 19:01:35 GMT 2023
|
Record UNII |
33X338MNE4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
33X338MNE4
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
31553
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
DTXSID8026018
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
651520
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
245-302-5
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
22888-70-6
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
m9941
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY | |||
|
300000005280
Created by
admin on Fri Dec 15 19:01:36 GMT 2023 , Edited by admin on Fri Dec 15 19:01:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|